MKTWHIGH SIGNALFINANCIAL10-K

MKTW executed a dramatic stock consolidation reducing outstanding shares by roughly 95% while experiencing declining profitability and cash position.

The massive reduction in share count from over 324 million to approximately 16 million shares suggests a significant reverse stock split, likely implemented to address the previously disclosed Nasdaq minimum bid price compliance issues. The simultaneous removal of earnout share language and Nasdaq delisting warnings indicates management may have successfully addressed immediate listing concerns, though at the cost of substantial shareholder dilution through the consolidation.

Comparing 2026-03-06 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

The company's financial performance deteriorated across key metrics, with operating income declining nearly 30% to $62.6M and net income falling 20% to $5.6M. Cash and equivalents dropped 28% to $70.1M while total assets contracted 16% to $218.4M, reflecting a company under financial pressure. The reduction in share buybacks from $10.8M to $3.4M further signals management's focus on preserving cash during this challenging period.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-68.7%
$10.8M$3.4M

Buyback activity reduced 68.7% — capital being redeployed elsewhere or cash conservation underway.

Operating Income
P&L
-29.7%
$89.0M$62.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Cash & Equivalents
Balance Sheet
-28.3%
$97.9M$70.1M

Cash decreased 28.3% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-22%
$168.8M$131.7M

Current assets declined 22% — monitor working capital adequacy and short-term liquidity.

Net Income
P&L
-20.4%
$7.1M$5.6M

Net income declined 20.4% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
-15.9%
$259.5M$218.4M

Total assets contracted 15.9% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-11%
$9.9M$8.8M

R&D spending cut 11% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-06
PRIOR — 2025-03-06
ADDED
As of March 2, 2026, there were 2,448,135 shares of the registrant s Class A common stock, with a par value of $0.0001 per share ( Class A common stock ) and 13,612,641 shares of the registrant s Class B common stock, with a par value of $0.0001 per share ( Class B common stock, together with Class A common stock, the common stock ), outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 41 Item 7A.
We have a subscriber base of approximately 374 thousand Paid Subscribers.
Through 9 primary customer facing brands, we currently have 22 free products and 112 paid products.
Our software and analytical tool solutions represented 52% of our Billings in 2025.
+7 more — sign up free →
REMOVED
As of March 3, 2025, there were 45,013,797 shares of the registrant s Class A common stock, with a par value of $0.0001 per share ( Class A common stock ) and 279,490,147 shares of the registrant s Class B common stock, with a par value of $0.0001 per share ( Class B common stock, together with Class A common stock, the common stock ), outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 7A.
Under certain circumstances, the Sponsor (as defined below), as well as certain members of our management team, are entitled to the Sponsor Earnout Shares (as defined below) and the Management Member Earnout Shares (as defined below).
Those earnout shares would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
The Nasdaq has notified us that we are not in compliance with Nasdaq s minimum bid price requirements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →